Overview
VTRS market data
Price History
VTRS price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.00 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.90 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 270.3% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $8.63 – $18.07 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $20.7K · P/B 0.97 · P/S 1.42.
Company News
Viatris Receives EMA CHMP Recommendation For Approval Of Ruxolitinib Viatris For The Treatment Of Myelofibrosis, Polycythaemia Vera And Graft-Vs-Host DiseaseBenzinga · Jul 24, 2026, 10:35 AM
Shares of generic drug companies are trading lower after President Trump announced that imported generics will be subject to a 100% import tariff following a two-year grace period in order to encourage reshoring of pharma manufacturing.Benzinga · Jul 22, 2026, 4:27 PM
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend YieldsBenzinga · Jul 14, 2026, 11:30 AM
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?The Motley Fool · Jul 9, 2026, 5:15 PM
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?The Motley Fool · Jul 6, 2026, 6:15 PM
8-K filing — Viatris Inc (VTRS)SEC EDGAR · Jul 1, 2026, 8:20 PM
Viatris’ VR‑205 Phase 3 Trial in Japan Met Primary and Key Secondary Endpoints; Safety Profile Aligned With Global Studies, NDA Filing Planned by End‑2026Benzinga · Jun 29, 2026, 11:10 AM
Viatris Warns Creon 25,000 And 35,000 Unit Capsule Supply Constraints In Australia To Continue Until January 31, 2027 Due To Unexpected Global Demand SurgeBenzinga · Jun 11, 2026, 7:44 AM
Tacrolimus Market Research Report 2026: Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2035Globenewswire Inc · May 25, 2026, 11:00 AM
Viatris' New Drug Application For Moderate-To-Severe Acute Pain Treatment Receives FDA's Acceptance For ReviewBenzinga · May 18, 2026, 12:15 PM